AU635050B2 - Method for diagnosis of periodontal disease by detection of alanine aminotransferase - Google Patents
Method for diagnosis of periodontal disease by detection of alanine aminotransferase Download PDFInfo
- Publication number
- AU635050B2 AU635050B2 AU59782/90A AU5978290A AU635050B2 AU 635050 B2 AU635050 B2 AU 635050B2 AU 59782/90 A AU59782/90 A AU 59782/90A AU 5978290 A AU5978290 A AU 5978290A AU 635050 B2 AU635050 B2 AU 635050B2
- Authority
- AU
- Australia
- Prior art keywords
- crevicular fluid
- periodontal disease
- fluid
- alt
- alanine aminotransferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/805—Test papers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Disclosed are methods for determining the presence of periodontal disease in mammals. The methods include the steps of (1) sampling gingival crevicular fluid, (2) assaying the crevicular fluid sample by colorimetric or other means to determine levels of alanine aminotransferase present, and (3) correlating the levels of L-alanine aminotransferase present in the crevicular fluid sample with a standard which is indicative of the presence of periodontal disease.
Description
6 35 r) 5l COMMONWEATTH OF ATISTRALTA FORM PATENTS ACT 1952 COMPLETE SPECIFICATION FOR OFFICE USE: Class Int.Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: *Priority: Related Art: a.
Name of Applicant: Address of Applicant: Actual Inventor:
S
XYTRONYX, INC.
6555 Nancy Ridge Drive, San Diego, California 92121, United States of America Peter Baram Address for Service: SHELSTON WATERS, 55 Clarence Street, Sydney Complete Specification for the Invention entitled: "METHOD FOR DIAGNOSIS OF PERIODONTAL DISEASE BY DETECTION OF ALANINE AMINOTRANSFERASE" The following statement is a full description of this invention, including the best method of performing it known to us:- 1 la- 'METHOD FOR DIAGNOSIS OF PERIODONTAL DISEASE BY DETECTION OF ALANINE AMINOTRANSFERASE" BACKGROUND OF THE INVENTION The present invention relates generally to methods for determining the presence of active S" periodontal disease in mammals through assaying gingival 15 crevicular fluid for the presence of intracellular enzymes. Specifically, the invention relates to methods for the determination of periodontal disease through assaying crevicular fluid for the presence of elevated levels of the enzyme alanine aminotransferase (ALT).
ALT is an intracellular enzyme widely distributed among mammalian tissues. Following acute tissue injury in the course of disease, trauma or toxicity, damaged cells release ALT into the circulation, interstitial fluid, inflammatory exudate and other bodily fluids. Elevated ALT in humans is indicative of tissue injury, most often associated with diseases of the liver.
Periodontal diseases are inflammatory diseases oo 3 of microbial etiology affecting the supporting tissues of the teeth. The term "periodontal disease" encompasses two major and distinct subclasses of disease, gingivitis and periodontitis. Gingivitis is characterized by inflammation of the gums without bone loss or loss of connective tissue attachment.
Gingivitis is a precondition for, but does not necessarily lead to, periodontitis which is 2 characterized by progressive formation of periodontal pockets between the gum tissue and tooth, resulting from loss of connective tissue attachment and bone loss, eventually leading to tooth loss. Presently available methods of measuring periodontal disease include subjective observational indices such as those of Loe, H. and P. Silness, Acta Odont. Scand., 21:533 (1963) for gingivitis, and Ramfjord, J. Periodontal., 38:602 (1967) for periodontitis. These indices for periodontitis are based on criteria such as bleeding on gentle probing, pocket depth, attachment loss, and radiographic evidence of bone loss. Unfortunately, these clinical indicators, with the exception of bleeding on probing, are generally acknowledged to be 15 reflective of past disease and prior damage. Of these indicators, only bleeding on probing (bleeding of gum tissue due to probing of the gum line or pocket with a hard instrument, probe or curet) has been claimed to correlate with active periodontal disease.
Nevertheless, bleeding itself is a subjective indicator of disease and the diagnostic value of bleeding on probing has been questioned, as such bleeding appears to be associated with a high proportion of false positive indications of periodontal disease. See Haffajee, A.D., S.S. Socransky and J.M. Goodson, J. Clin. Perio., 10:257-265 (1983).
Other methods have been proposed for the diagnosis of periodontal disease. Because both gingivitis and periodontitis are characterized by accumulation and flow of crevicular fluid (a transudate of serum) at the gingival sulcus and pockets, measurement of the volume of crevicular fluid present at a site has been proposed as a diagnostic method for the detection of periodontal disease. An instrument known as the Periotron (Harco Electronics Ltd.; Winnipeg, Canada) makes use of this principle by galvanometrically 3 measuring the volume of crevicular fluid absorbed by small strips of porous material known as Periopaper (Harco; Tustin, California) which are inserted into the crevicular space between the tooth and gum.
Still other methods relate to analysis of components of crevicular fluid for the diagnosis of periodontal disease. Kornman, J. Period. Res., 22, (1987) discloses methods correlating the presence of collagenase in crevicular fluid with the severity of periodontal disease. A device (Periocheck, Advanced Clinical Technologies, Inc., Westwood, Mass.) is available which assays for neutral proteases to determine the presence of periodontal disease. The source of both collagenase and neutral proteases has 15 been suggested to be polymorphonuclear leucocytes migrating into the crevice. Other components of crevicular fluid such as chondroitin-4-sulfate, the presence of which is considered indicative of bone destruction, have been found to differ in crevicular fluid associated with gingivitis and crevicular fluid associated with periodontitis. Prostaglandin E 2 a mediator of inflammation, has also been indicated to be associated more closely with periodontitis than with gingivitis.
S 25 The enzyme aspartate aminotransferase (AST) is an intracellular enzyme widely distributed among tissues and organs of the body. Elevated levels of AST in the blood and other bodily fluids is indicative of tissue inflammation and cellular damage. In particular, AST has been used in the detection of disorders of the liver, heart and skeletal muscles. The ratio of AST to ALT (formerly SGOT/SGPT ratio) is useful in assessing the extent of hepatic damage; the greater the ratio, the worse the damage.
It has been found that elevated levels of AST in crevicular fluid is highly correlative with the 4 presence of active periodontal disease. (See abstracts presented at the American Association for Dental Research Meetings, Cincinnati, Ohio, March 17-20, 1983: Crawford, S. Mukherjee, D.A. Chambers and R. Cohen, Abstract No. 241; and Mukherjee, J.
Crawford, D.A. Chambers and R. Cohen, Abstract No. 242; Chambers, J.M. Crawford, S. Mukherjee and R.
Cohen, J. Periodon., 55, No. 9, 526-530, Sept. 1984).
The Crawford, et al. abstract discloses a study with dogs in which gingivitis and periodontitis were induced experimentally. Specifically, gingival health was established in five beagles and gingivitis was then S, allowed to develop for four weeks by introduction of a "soft diet and withdrawal of brushing. Periodontitis was 15 then induced by ligation of the dogs' teeth. Crevicular S. fluid samples were collected at weekly intervals in volumetric capillary tubes after isolation and drying of teeth. The abstract indicates that crevicular fluid obtained during the incidence of experimental periodontitis contained concentrations of AST (3209 L435 (SFU/ml) approximately ten-fold higher at their peak than prior to ligation (468 164 SFU/ml) and further that crevicular fluid during the incidence of experimental gingivitis contained approximately ten-fold 25 higher concentrations of AST than in serum (41 4 SFU/ml).
The Chambers, et al., J. Periodont.
publication describes the dog study in greater detail 0 and notes that the average AST levels in crevicular fluid correlated neither with clinical estimations of attachment levels nor with gingival inflammation. The article did note, however, that the peak of AST activity occurring 2 weeks after ligation of teeth did coincide with the period of high levels of soft tissue destruction and osteoclast activity reported in the beagle dog model and with the period of active bone 5 resorption in ligature-induced periodontitis in the monkey model. The article also disclosed that the level of AST in crevicular fluid did not correlate with enzyme levels in dental plaque, suggesting the absence of bacterial origin for the enzyme.
The Mukherjee Abstract describes measurement of AST levels in human crevicular fluid collected in volumetric capillary tubes from areas diagnosed as having gingivitis or periodontitis according to the periodontal disease index (PDI) of Ramfjord. Disease activity indicated by the presence or absence of bleeding upon probing was also noted. AST .concentrations of crevicular fluid collected from areas S showing no bleeding on probing 0 SFU/ml minimal 15 bleeding 464 113 SFU/ml and definite bleeding 595 192 SFU/ml The analysis of data sorted according to gingivitis and periodontitis showed *0 363 182 SFU/ml and 424 119 SFU/ml respectively. The Abstract notes that the level of AST in crevicular fluid may correlate with the disease activityas determined by bleeding on probing.
While the references fail to demonstrate a specific positive association between elevated AST activity in gingival crevicular fluid and either S 25 attachment loss or gingival inflammation, they do indicate that there exists a general association between elevated AST levels in gingival crevicular fluid and periodontal disease activity as determined by bleeding .on probing. Chambers, European Patent Application No. 151,536 published August 14, 1985 based on U.S.
Patent Application Serial No. 575, 552 filed January 31, 1984, the disclosure of which is hereby incorporated by reference, relates to the work embodied in the article and abstracts and the recognition of the general relationship between elevated AST levels and periodontal disease activity. The application describes diagnostic 6 methods based on the recognition that the presence of elevated levels of AST in crevicular fluid is predictive of a high probability of progressive, as opposed to nonprogressive, periodontal disease and corresponding tissue damage.
According to a method described in the Chambers patent application, the crevicular fluid is collected from the gingival sulcus by means such as a microsyringe, capillary tube or absorbent strip. The volume of material is measured and the concentration of AST in the collected sample of crevicular fluid is determined by either colorimetric or immunological assay. The patent application describes a method for S determining the presence of active periodontal disease in mammals comprising assaying crevicular fluid for the presence of elevated levels of aspartate aminotransferase. The application defines elevated levels as being an amount of AST substantially in excess of the level of AST normally found in the blood stream of healthy adults of the species being tested which ranges from about 4 to about 32 milli-International Units/ml (mIU/ml) depending upon the precise testing protocol used.
In addition to the work by the Chambers, et 25 al. group on AST, the relationship between other tissue and bacterial enzymes and periodontal diseases has been studied. Lamster, et al., J. Periodontal., 56, 139-147 (1985), disclose studies assessing crevicular fluid 3 volume and activity of the enzymes lactate dehydrogenase (LDH), 6-glucuronidase (BG) and arylsulfatase (AS) in crevicular fluid during the development of experimental gingivitis. Bang, et al., Helv. Odont. Acta., 16:89 (1972); Weinstein, et al., Archs. Oral Biol., 17:375 (1972) and Snyder, et al., J. Dent. Res., 62:196 (1983) relate to the presence of LDH in gingival crevicular fluid and the correlation of LDH with parameters of 7 periodontal disease. Bang, et al., Archs. Oral Biol., 15:445-541 (1970) relate to the correlation of BG with gingival inflammation.
LDH is said to be derived primarily from cells in the sulcular epithelium, but fibroblasts and polymorphonuclear leucocytes that lyse in the crevice also contribute to the LDH pool. BG is said to be primarily derived from degradation of lysosomal granules of infiltrating polymorphonuclear leucocytes and macrophages. The pattern of AS activity was characterized as being between that of LDH and BG with sources of this enzyme including polymorphonuclear S. leucocytes, mast cells and fibroblasts.
Crevicular fluid "resting" volumes were 15 determined by inserting a filter paper strip into the gingival sulcus until mild resistance was felt and leaving the strip in place for 30 seconds before removing the strip and determining the volume of fluid absorbed. After removal of the strip, the crevicular fluid "flow" volume was determined by waiting 30 seconds and inserting a second filter paper strip into the site for 3 seconds. Analysis of data collected from subjects subjected to experimental gingivitis indicated that while clinical inflammation increased during the 4 weeks 25 of the study, the concentrations and total activity (concentration times sample volume) of BG and AS rose during the onset of gingivitis but peaked or leveled off after reaching a maximum 2 or 3 weeks into the study.
S, 3 The data indicated that an increase in fluid volume S" 30 without a corresponding increase in BG or AS activity occurred during the latter part of the trial. The increase in LDH concentration and total activity during the experiment was not dramatic and was consistent with an earlier experiment wherein the concentration of LDH in crevicular fluid was higher in subjects with healthy gingiva than with mildly inflamed gingiva. Lamster, et 8 al. also suggested that reporting of crevicular fluid constituent data in terms of concentration alone might be inadequate and that it might be desirable to report enzyme data in terms of both concentration and total activity of the sample.
Lamster, et al., J. Clin. Periodontal., 13, 799-804 (1986), present data wherein LDH, BG and AS concentrations and total activities for 30 second samples were assayed for a group of periodontitis patients and a control group. Negative or low positive correlation coefficients were determined between enzyme concentrations and gingival index (GI) and probing depth. On the other hand, a "modest, but not absolute" "correlation between increasing severity of pathology and *4 15 total enzyme activity for a 30 second sample was suggested by the data. Lamster, et al. suggested, therefore, that total activity in a standardized sample S. might be a more appropriate means of reporting crevicular fluid constituent data.
More recently, co-owned Chambers, et al. U.S.
Patent Application Serial No. 262,995 filed October 26, 1988, the disclosure of which is incorporated herein by o0.. reference, revealed the results of an experimental study of ligature-induced periodontitis in dogs and a 25 longitudinal study of periodontitis patients, regarding measurement of activity of AST in gingival crevicular fluid (GCF). In the application, it was shown that the total activity of AST present in a GCF sample taken for a selected brief period of time provided a better 30 correlation with periodontal disease activity than did assaying for the AST concentration of GCF. In addition, it was found that the total AST activity in the GCF samples was indicative of both the severity and type of periodontal disease, either gingivitis or periodontitis.
In spite of the various advances made in the art, a simple, reliable means for an enzymatic -9 determination of the presence of periodontal disease is desired. Such a method might be used for .jiagnosis of such disease or for determination of the efficacy of treatment of that periodontal disease condition. The monitoring of periodontal disease is a nontrivial concern because of the serious nature of continuing or repeating treatments for periodontitis, which involve administration of drugs, root planing or surgery.
Cc, rent methods such as monitoring of the clinical parameters of probing depths and radiographic interpretations of the bone provide only a belated t evaluation of treatment efficacy. Accordingly, improved approaches are clearly desired.
15 SUMMARY OF THE INVENTION The invention relates to methods for determining the presence of active periodontal disease in mammals. The invention also provides a method for determining the efficacy of treatment of periodontal disease conditions. Specifically, such methods comprise assaying_crevicular fluid for the presence of elevated levels of the enzyme ALT. It has been found that levels of ALT present in crevicular fluid correlate with indicators of periodoital disease severity and past disease and that levels elevated over those normally found in the crevicular fluiid of those having no past history or present indications of periodontal disease are indicative of the presence, severity and type of S" active periodontal disease.
According to methods of the invention, gingival crevicular fluid (GCF) is sampled from the interface of the gum and tooth and is assayed for the presence of ALT. According to one method, the concentration of ALT in the GCF sample is determined and is compared to a standard indicative of the presence of periodontal disease. According to a preferred 10 embodiment of the invention, GCF is collected from a given site in the gingival sulcus for a selected brief period of time, preferably of from about one second to about 3 minutes and most preferably from about 5 to seconds. GCF samples so obtained will be of varying volumes depending upon the condition of the specific sample site. The GCF so sampled, of whatever volume, is then assayed to determine, not the concentration, but the total activity of ALT present. The total activity of ALT in the sample so assayed is then correlated with a standard established for the selected period of sampling time, which standard is indicative of the presence, type or severity of periodontal disease. The improved methods of the invention are not only useful for the diagnosis of periodontal disease but are also useful for determining the efficacy of treatment of o periodontal disease conditions by determining the activity of the periodontal disease condition at a gingival site subjected to such treatment.
DETAILED OESCRIPTION According to practice of the invention, gingival crevicular fluid is sampled from the intracrevicular space between the teeth and gum tissue. The fluid samipled during that time is then assayed to determine the concentration of ALT, accoraing to chemical or immunological methods well known to the art. The concentration of ALT determined is then correlated with a standard which is indicative of the presence of active periodontal disease. When the ALT concentration is in excess of the standard, the presence of active periodontal disease is indicated.
In a preferred embodiment of the invention, the crevicular fluid is collected from a particular site in the gingival sulcus for a selected brief period of time. The entire volume of fluid obtained during that 11 time period is then assayed for the tal activity of ALT, again using methods well known >o the art. The total quantity of ALT thus determined for the sample is then compared with a standard established for the selective sampling period, which is indicative of the presence, type or severity of active periodontal disease.
Crevicular fluid may be collected from the gingival sulcus by a variety of means according to the present invention including a microsyringe with a fine (preferably blunt) needle or a capillary tube which need not be calibrated. Samples may also be obtained by means of pledgets, cotton swabs or filamentous material such as dental floss. Preferably, such fluid is sampled 15 by means of absorbent strips of paper such as those known as Periopaper (Harco; Tustin, California). The sample is collected by direct contact of the sampling means with crevicular fluid at the gingival sulcus. The sample means should be of sufficient capacity to accommodate the volume of crevicular fluid collected for a selected sampling period. It is generally desirable that this volume should be less than or equal to about 1 pi but the sample volume could be substantially higher 5 from 1-10 ul) when the flow rate is greatly elevated. The fluid sampled can be less than the total capacity of the sample means. The absence of fluid or of ALT enzyme at a crevicular site is generally \o indicative of health and may be interpreted as such. It is not necessary that the absorbent means measure the volume of the fluid absorbed, but it is generally desired that the means absorb all of the fluid in the crevicular space.
The preferred method of the invention involves sampling of crevicular fluid according to a specific methodology whereby crevicular fluid at a given site is sampled over a selected standardized brief period, 12 preferably of from about 5 seconds to about 3 minutes and most preferably from about 5 to 30 seconds. The sampling period must be uniform with respect to the standard selected in order to determine the presence, type or severity of periodontal disease. The oral fluid sample, obtained by whatever means, is then assayed to determine the total quantity of ALT present. Chemical or immunological methods (including the use of monoclonal antibodies specific for ALT) such as are well known in the art may be used to conduct such analysis.
For example, in Lott, et al., "Clinical Enzymology: A Case-Oriented Approach," Chapter 6, 132, 1986, it is noted that a well known reaction scheme for determination of ALT is as follows: 15 ALT L-alanine 2-oxoglutarate 4-- 0 L-glutamate pyruvate
LD
Pyruvate NADH lactate NAD.
(where LD is lactate dehydrogenase, and NAD is nicotine adenine dinucleotide).
As the quantity of NADH decreases, due to the second reaction, the decrease in absorbence with time is followed at 340 nm. Other reaction schemes for the determination of ALT activity would be readily apparent to those of skill in the art. Such schemes could use a wide variety of materials including diazo dyes for the determination of ALT activity. ALT is a very stable enzyme; its values do not change in 24 hours, and it is stable for at least one week at 4 0
C.
EXAMPLE 1 As part of an ongoing longitudinal study of periodontitis, patients enrolled in a quarterly 13 maintenance therapy program for more than two years, ALT activity was measured in gingival crevicular fluid (GCF) samples collected from 19 of these patients. The GCF samples were collected over a period of 30 seconds, for 8 periodontal sites per subject for a total of 152 sites. The total activity of ALT in each GCF sample was measured. These sites were also evaluated clinically for evidence of severity of inflammation or past periodontitis.
The results are shown in Tables 1 and 2. In Table 1, it is shown that those sites with the most severe inflammation (Gingival Index 2 and GCF volume greater than 0.4 ul) tended to have elevated levels of ALT activity. In Table 2, it is seen that those sites 15 with evidence of having suffered the most disease in the past (pocket depth greater than 4 mm and probing attachment level greater than 7 mm) also tended to have elevated ALT. These results demonstrate a positive association between ALT activity and indicators of disease severity or past disease.
0o 0 0 0 00 3
S
4 4 *54 C S C S C S C C C C C CO S 4 S S C *S S CC. C *CC C S C C S C C S C. C C S S U C CC S C S 5 5* C CS C S *C* TABLE 1 ASSOCIATION OF GCF ALT WITH CLINICAL MEASUREMENTS OF PERIODONTAL INFLAMM4ATION mean ALT activity for a sec.
sample (jiIU) 0 307 Gingival Index 409 2 1141 0-0. 2 356 0. 21-0.4 414 0.4 Crevicular Fluid Voluate (4l) 1111 TABLE 2 ASSOCIATION OF GCF ALT WITH CLINICAL MEASUREMENTS OF PAST PERIODONTAL DISEASE Probinq Pocket Depth (mm) Probing Attachment Level (mm) 1-3 4 2-5 5-7 7 mean ALT activity for a sec.
sample
(PIU)
335 619 1789 330 1196 15 Numerous modifications and variations of the above-described invention are expected to occur to those of skill in the art. In particular, it is expected that modifications of the assay procedures will be developed for colorimetric assay kits indicative of the potential presence of periodontal disease. Accordingly, only such limitations as appear in the following claims should be placed thereon.
to 0 9 or O O ee r *o 0
*S
S
5e@e b* S C..3 or
Claims (10)
1. A method for determining the presence of active periodontal disease in mammals, comprising assaying gingival crevicular fluid for the presence of elevated levels of alanine aminotransferase.
2. The method according to claim 1 comprising assaying gingival crevicular fluid for the presence of elevated concentrations of alanine aminotransferase.
3. The method according to claim 1 wherein the gingival crevicular fluid is sampled for a selected brief period of time, between 1 second and 3 minutes, and the total quantity of alanine aminotransferase in 15 the fluid is determined. *t*
4. The method according to claim 3 wherein the crevicular fluid is sampled for a selected brief period of between 5 seconds and 30 seconds.
5. The method of claim 1 wherein the crevicular fluid is sampled by means of a capillary tube. a
6. The method of claim 1 wherein the crevicular fluid is sampled by means of a syringe.
7. The method of claim 1 wherein the crevicular fluid is sampled by means of an absorbent strip.
8. The method of claim 1 wherein said assay is a colorimetric assay.
9. The method of claim 1 wherein said assay is an immunological assay. 17 A method for determining the efficacy of treatment of periodontal disease conditions, comprising assaying gingival crevicular fluid for the presence of elevated levels of alanine aminotransferase.
11. A method for determining the presence of periodontal disease in mammals substantially as herein described with reference to the example. DATED This 30th Day of December 1992 XYTRONYX, INC. Attorney: IAN T. ERNST Fellow Institute of Patent Attorneys of Australia of SHELSTON WATERS e a
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/310,789 US4981787A (en) | 1989-02-14 | 1989-02-14 | Method for diagnosis of periodontal disease by detection of L-alanine aminotransferase |
| AT90904041T ATE103990T1 (en) | 1989-02-14 | 1990-01-17 | METHOD OF DIAGNOSIS OF PERIODONTAL DISEASE BY DETECTING ALANINAMINOTRANSFERASE. |
| DK90904041.2T DK0412148T3 (en) | 1989-02-14 | 1990-01-17 | Method for diagnosis of periodontal disease by detection of alanine aminotransferase |
| EP90904041A EP0412148B1 (en) | 1989-02-14 | 1990-01-17 | Method for diagnosis of periodontal disease by detection of alanine aminotransferase |
| ES90904041T ES2063343T3 (en) | 1989-02-14 | 1990-01-17 | METHOD FOR DIAGNOSING A PERIODONTAL DISEASE FROM ALANINE-AMINOTRANSFERASE DETECTION. |
| PCT/US1990/000211 WO1990009589A1 (en) | 1989-02-14 | 1990-01-17 | Method for diagnosis of periodontal disease by detection of alanine aminotransferase |
| JP2504314A JPH074274B2 (en) | 1989-02-14 | 1990-01-17 | Diagnostic method for periodontal disease by detection of alanine aminotransferase |
| DE69007898T DE69007898T2 (en) | 1989-02-14 | 1990-01-17 | METHOD FOR DIAGNOSING PERIODONTAL DISEASE BY DETECTING ALANINE AMINOTRANSFERASE. |
| CA002009813A CA2009813C (en) | 1989-02-14 | 1990-02-12 | Method for diagnosis of periodontal disease by detection of alanine aminotransferase |
| AU59782/90A AU635050B2 (en) | 1989-02-14 | 1990-07-24 | Method for diagnosis of periodontal disease by detection of alanine aminotransferase |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/310,789 US4981787A (en) | 1989-02-14 | 1989-02-14 | Method for diagnosis of periodontal disease by detection of L-alanine aminotransferase |
| AU59782/90A AU635050B2 (en) | 1989-02-14 | 1990-07-24 | Method for diagnosis of periodontal disease by detection of alanine aminotransferase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5978290A AU5978290A (en) | 1992-06-11 |
| AU635050B2 true AU635050B2 (en) | 1993-03-11 |
Family
ID=25632586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU59782/90A Ceased AU635050B2 (en) | 1989-02-14 | 1990-07-24 | Method for diagnosis of periodontal disease by detection of alanine aminotransferase |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4981787A (en) |
| EP (1) | EP0412148B1 (en) |
| JP (1) | JPH074274B2 (en) |
| AT (1) | ATE103990T1 (en) |
| AU (1) | AU635050B2 (en) |
| CA (1) | CA2009813C (en) |
| DE (1) | DE69007898T2 (en) |
| DK (1) | DK0412148T3 (en) |
| ES (1) | ES2063343T3 (en) |
| WO (1) | WO1990009589A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834226A (en) * | 1991-01-31 | 1998-11-10 | Xytronyx, Inc. | One-step test for aspartate aminotransferase |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US5366870A (en) * | 1993-04-02 | 1994-11-22 | Xytronyx, Inc. | Limited enzyme assay for aminotransferases |
| KR100251594B1 (en) * | 1995-04-12 | 2000-06-01 | 알카 쿠보넨 | Diagnosis of the Periodontal Fascia Disease and Methods for Predicting its Risk and Test Kits Used Thereof |
| CA2204616C (en) * | 1995-09-18 | 2002-12-17 | Ranjan Mukherjee | Ppar gamma antagonists for treating obesity |
| US6063588A (en) * | 1996-11-14 | 2000-05-16 | The Trustees Of Columbia University In The City Of New York | Method of diagnosing periodontal disease |
| CN1086205C (en) * | 1998-04-03 | 2002-06-12 | 北京远东协和生物技术有限公司 | Kit for determining alanine aminopherase |
| JP2004129584A (en) * | 2002-10-11 | 2004-04-30 | Applied Cell Biotechnologies Inc | Method for inspecting periodontal disease, and diagnostic medicine for inspection |
| CA2515348A1 (en) * | 2003-02-05 | 2004-08-26 | The General Hospital Corporation | A microchip-based system for hiv diagnostics |
| JP3599283B1 (en) * | 2003-06-30 | 2004-12-08 | 株式会社エーシーバイオテクノロジーズ | A method for determining the onset of periodontitis. |
| SE0400191D0 (en) | 2004-01-30 | 2004-01-30 | Tendera Ab | A test kit for detecting periodontal disease |
| JP2008511079A (en) * | 2004-08-24 | 2008-04-10 | シーレーテ エルエルシー | Systems and methods related to immune system enhancement |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691018A (en) * | 1970-10-28 | 1972-09-12 | Warner Lambert Co | Diagnostic method for periodontal disease |
| JPS5597563A (en) * | 1979-01-13 | 1980-07-24 | Rikagaku Kenkyusho | Gate valve |
| JPS5722698A (en) * | 1980-07-18 | 1982-02-05 | Kokusai Shiyaku Kk | Determination of got activity |
| JPS58130075A (en) * | 1982-12-21 | 1983-08-03 | 株式会社ソフイア | Player registering type control system for electronic control type pinball machine |
| JPS59169766A (en) * | 1983-03-14 | 1984-09-25 | Matsushita Electric Ind Co Ltd | polishing tools |
| JPS6024181A (en) * | 1983-07-15 | 1985-02-06 | Unitika Ltd | Hybridoma cell strain |
| IL74191A0 (en) * | 1984-01-31 | 1985-04-30 | Univ Illinois | Method and kit for determining periodontal disease |
| JPS60169766A (en) * | 1984-02-14 | 1985-09-03 | Sugiura Shinyaku Kaihatsu Kenkyusho:Kk | Reagent for fractional measurement of soluble fraction aspartic acid aminotransferase and mitochondria aspartic acid aminotransferase |
| US4801535A (en) * | 1986-03-18 | 1989-01-31 | Xytronyx, Inc. | Method for detection of periodontal disease |
-
1989
- 1989-02-14 US US07/310,789 patent/US4981787A/en not_active Expired - Fee Related
-
1990
- 1990-01-17 AT AT90904041T patent/ATE103990T1/en not_active IP Right Cessation
- 1990-01-17 DE DE69007898T patent/DE69007898T2/en not_active Expired - Fee Related
- 1990-01-17 EP EP90904041A patent/EP0412148B1/en not_active Expired - Lifetime
- 1990-01-17 ES ES90904041T patent/ES2063343T3/en not_active Expired - Lifetime
- 1990-01-17 WO PCT/US1990/000211 patent/WO1990009589A1/en not_active Ceased
- 1990-01-17 JP JP2504314A patent/JPH074274B2/en not_active Expired - Lifetime
- 1990-01-17 DK DK90904041.2T patent/DK0412148T3/en active
- 1990-02-12 CA CA002009813A patent/CA2009813C/en not_active Expired - Fee Related
- 1990-07-24 AU AU59782/90A patent/AU635050B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU5978290A (en) | 1992-06-11 |
| DE69007898T2 (en) | 1994-07-21 |
| US4981787A (en) | 1991-01-01 |
| EP0412148A1 (en) | 1991-02-13 |
| DE69007898D1 (en) | 1994-05-11 |
| ES2063343T3 (en) | 1995-01-01 |
| WO1990009589A1 (en) | 1990-08-23 |
| CA2009813A1 (en) | 1990-08-14 |
| ATE103990T1 (en) | 1994-04-15 |
| JPH074274B2 (en) | 1995-01-25 |
| JPH03501447A (en) | 1991-04-04 |
| DK0412148T3 (en) | 1994-05-02 |
| EP0412148A4 (en) | 1991-04-24 |
| CA2009813C (en) | 1997-09-09 |
| EP0412148B1 (en) | 1994-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nakashima et al. | A longitudinal study of various crevicular fluid components as markers of periodontal disease activity | |
| Page | Host response tests for diagnosing periodontal diseases | |
| Lamster | Evaluation of components of gingival crevicular fluid as diagnostic tests | |
| Lamster et al. | Development of a biochemical profile for gingival crevicular fluid: methodological considerations and evaluation of collagen‐degrading and ground substance‐degrading enzyme activity during experimental gingivitis | |
| Loesche et al. | Multi‐center clinical evaluation of a chairside method for detecting certain periodontopathic bacteria in periodontal disease | |
| CA2553087C (en) | Detection of periodontal disease by detecting co-existence of bacterial and human substances in an oral cavity | |
| AU635050B2 (en) | Method for diagnosis of periodontal disease by detection of alanine aminotransferase | |
| EP0523079A1 (en) | System for diagnosing periodontal disease | |
| Lamster et al. | Current status of tests for periodontal disease | |
| US6277587B1 (en) | Method of testing for periodontal disease | |
| US5047328A (en) | Method for determination of the type and severity of periodontal disease states | |
| Hannigan et al. | Soluble cell adhesion molecules in gingival crevicular fluid in periodontal health and disease | |
| Eley et al. | Protease activities in peri‐implant sulcus fluid from patients with permucosal osseointegrated dental implants. Correlation with clinical parameters | |
| Amalfitano et al. | The effects of incubation length and temperature on the specificity and sensitivity of the BANA (N‐benzoyl‐DL‐arginine‐naphthylamide) test | |
| Biswas et al. | Study of crevice fluid in relation to periodontal disease in children: II. Effect of age, sex and gingival inflammation on crevice fluid protein, carbohydrate, total calcium, phosphate and nitrogen | |
| AU626523B2 (en) | Diagnostic methods, product and kits for detecting peridontal diseases | |
| Shimada et al. | Relationship between levels of aspartate aminotransferase in gingival crevicular fluid and conventional measures of periodontal status assessed using PocketWatchTM: A cross-sectional study | |
| IL95177A (en) | Method for diagnosis of periodontal disease by detection of alanine aminotransferase. | |
| EP0176246A2 (en) | Method and kit for detecting the presence of gum disease | |
| NZ234623A (en) | Method for diagnosis of periodontal disease by detection of alanine aminotransferase (alt) | |
| Smith et al. | Salivary amylase in crevicular fluid | |
| Dewan et al. | Evaluation of aspartate aminotransferase enzyme levels in saliva and gingival crevicular fluid with periodontal disease progression-A pilot study. | |
| Priestland | Diagnosis, progression, prognostic indication and classification of periodontal disease: a review (Part 1) | |
| US4366144A (en) | In vivo method of determining leucocyte migratory activity levels | |
| Oezcakir et al. | Detection and measurements of soluble intercellular adhesion molecules at implants and teeth: A comparative study |